Cargando…
Multidrug-resistant Tuberculosis in Central Asia
Multidrug-resistant tuberculosis (MDR-TB) has emerged as a major threat to TB control, particularly in the former Soviet Union. To determine levels of drug resistance within a directly observed treatment strategy (DOTS) program supported by Médecins Sans Frontières in two regions in Uzbekistan and T...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323206/ https://www.ncbi.nlm.nih.gov/pubmed/15200821 http://dx.doi.org/10.3201/eid1005.030718 |
_version_ | 1782229151605850112 |
---|---|
author | Cox, Helen Suzanne Orozco, Juan Daniel Male, Roy Ruesch-Gerdes, Sabine Falzon, Dennis Small, Ian Doshetov, Darebay Kebede, Yared Aziz, Mohammed |
author_facet | Cox, Helen Suzanne Orozco, Juan Daniel Male, Roy Ruesch-Gerdes, Sabine Falzon, Dennis Small, Ian Doshetov, Darebay Kebede, Yared Aziz, Mohammed |
author_sort | Cox, Helen Suzanne |
collection | PubMed |
description | Multidrug-resistant tuberculosis (MDR-TB) has emerged as a major threat to TB control, particularly in the former Soviet Union. To determine levels of drug resistance within a directly observed treatment strategy (DOTS) program supported by Médecins Sans Frontières in two regions in Uzbekistan and Turkmenistan, Central Asia, we conducted a cross-sectional survey of smear-positive TB patients in selected districts of Karakalpakstan (Uzbekistan) and Dashoguz (Turkmenistan). High levels of MDR-TB were found in both regions. In Karakalpakstan, 14 (13%) of 106 new patients were infected with MDR-TB; 43 (40%) of 107 previously treated patients were similarly infected. The proportions for Dashoguz were 4% (4/105 patients) and 18% (18/98 patients), respectively. Overall, 27% of patients with positive smear results whose infections were treated through the DOTS program in Karakalpakstan and 11% of similar patients in Dashoguz were infected with multidrug-resistant strains of TB on admission. These results show the need for concerted action by the international community to contain transmission and reduce the effects of MDR-TB. |
format | Online Article Text |
id | pubmed-3323206 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-33232062012-04-17 Multidrug-resistant Tuberculosis in Central Asia Cox, Helen Suzanne Orozco, Juan Daniel Male, Roy Ruesch-Gerdes, Sabine Falzon, Dennis Small, Ian Doshetov, Darebay Kebede, Yared Aziz, Mohammed Emerg Infect Dis Research Multidrug-resistant tuberculosis (MDR-TB) has emerged as a major threat to TB control, particularly in the former Soviet Union. To determine levels of drug resistance within a directly observed treatment strategy (DOTS) program supported by Médecins Sans Frontières in two regions in Uzbekistan and Turkmenistan, Central Asia, we conducted a cross-sectional survey of smear-positive TB patients in selected districts of Karakalpakstan (Uzbekistan) and Dashoguz (Turkmenistan). High levels of MDR-TB were found in both regions. In Karakalpakstan, 14 (13%) of 106 new patients were infected with MDR-TB; 43 (40%) of 107 previously treated patients were similarly infected. The proportions for Dashoguz were 4% (4/105 patients) and 18% (18/98 patients), respectively. Overall, 27% of patients with positive smear results whose infections were treated through the DOTS program in Karakalpakstan and 11% of similar patients in Dashoguz were infected with multidrug-resistant strains of TB on admission. These results show the need for concerted action by the international community to contain transmission and reduce the effects of MDR-TB. Centers for Disease Control and Prevention 2004-05 /pmc/articles/PMC3323206/ /pubmed/15200821 http://dx.doi.org/10.3201/eid1005.030718 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
spellingShingle | Research Cox, Helen Suzanne Orozco, Juan Daniel Male, Roy Ruesch-Gerdes, Sabine Falzon, Dennis Small, Ian Doshetov, Darebay Kebede, Yared Aziz, Mohammed Multidrug-resistant Tuberculosis in Central Asia |
title | Multidrug-resistant Tuberculosis in Central Asia |
title_full | Multidrug-resistant Tuberculosis in Central Asia |
title_fullStr | Multidrug-resistant Tuberculosis in Central Asia |
title_full_unstemmed | Multidrug-resistant Tuberculosis in Central Asia |
title_short | Multidrug-resistant Tuberculosis in Central Asia |
title_sort | multidrug-resistant tuberculosis in central asia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323206/ https://www.ncbi.nlm.nih.gov/pubmed/15200821 http://dx.doi.org/10.3201/eid1005.030718 |
work_keys_str_mv | AT coxhelensuzanne multidrugresistanttuberculosisincentralasia AT orozcojuandaniel multidrugresistanttuberculosisincentralasia AT maleroy multidrugresistanttuberculosisincentralasia AT rueschgerdessabine multidrugresistanttuberculosisincentralasia AT falzondennis multidrugresistanttuberculosisincentralasia AT smallian multidrugresistanttuberculosisincentralasia AT doshetovdarebay multidrugresistanttuberculosisincentralasia AT kebedeyared multidrugresistanttuberculosisincentralasia AT azizmohammed multidrugresistanttuberculosisincentralasia |